Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Pan, Si Yuan ^a   Yu, Qing ^a   Zhang, Yi ^a   Wang, Xiao Yan ^a   Sun, Nan ^a   Yu, Zhi Ling ^b   Ko, Kam Ming ^c  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Fatty liver; Fenofibrate; Fructus schisandrae chinensis; Hepatomegaly; Hepatotoxicity; Hypercholesterolemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FENOFIBRATE; FRUCTUS SCHISANDRA CHINENSIS EXTRACT; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN; SCHISANDRA CHINENSIS EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; ENZYME ACTIVITY; FATTY LIVER; FRUCTUS SCHISANDRAE CHINENSIS; HEPATOMEGALY; HYPERCHOLESTEROLEMIA; LIPID DIET; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CYCLOOCTANES; DIET; DRUGS, CHINESE HERBAL; FENOFIBRATE; FRUIT; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIGNANS; LIPID METABOLISM; LIPIDS; LIVER; MICE; POLYCYCLIC COMPOUNDS; TRIGLYCERIDES;

MUS; SCHISANDRA;

EID: 84866268403     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-120     Document Type: Article

References (54)

1. Obesity and air pollution: Global risk factors for pediatric non-alcoholic fatty liver disease. Kelishadi R, Poursafa P, Hepat Mon 2011 11 794 802 22224077
2. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM, J Dig Dis 2011 12 125 130 10.1111/j.1751-2980.2011.00487.x 21401898
3. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Duan XY, Qiao L, Fan JG, Hepatobiliary Pancreat Dis Int 2012 11 18 27 10.1016/S1499-3872(11)60120-3 22251466
4. The effect of dyslipidemic drugs on mortality: a meta-analysis. Jain S, Vaishnavi V, Chakraborty BS, Indian J Pharmacol 2009 41 4 8 10.4103/0253-7613. 48878 20177573
5. Isoflavones as a smart curer for non-alcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling. Kim MH, Kang KS, Prev Med 2011 54 Suppl 57 S63 22227283
6. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Parnell JA, Raman M, Rioux KP, Reimer RA, Liver Int 2011 32 701 711 22221818
7. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Salamone F, Galvano F, Marino A, Paternostro C, Tibullo D, Bucchieri F, Mangiameli A, Parola M, Bugianesi E, Li Volti G, Dig Liver Dis 2011 44 33 42
8. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ, Hepatology 2011 54 1610 1619 10.1002/hep.24544 21748765
9. The effect on the blood lipid profile of soy foods combined with a prebiotic: a randomized controlled trial. Wong JM, Kendall CW, de Souza R, Emam A, Marchie A, Vidgen E, Holmes C, Jenkins DJ, Metabolism 2010 59 1331 1340 10.1016/j.metabol.2009.12.017 20096897
10. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. Panossian A, Wikman G, J Ethnopharmacol 2008 118 183 212 10.1016/j.jep.2008.04.020 18515024
11. Schisandrin B enhances the glutathione redox cycling and protects against oxidant injury in different types of cultured cells. Lam PY, Leong PK, Chen N, Ko KM, Biofactors 2011 37 439 446 10.1002/biof.179 22034285
12. Effect of bicyclol on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice. Yu YN, Chen H, Li Y, Basic Clin Pharmacol Toxicol 2009 104 300 305 10.1111/j.1742-7843.2008.00343.x 19210495
13. Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study. Cui S, Wang M, Fan G, Nat Med J Chin 2002 82 538 540 Chinese
14. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Pan SY, Yang R, Dong H, Yu ZL, Ko KM, Eur J Pharmacol 2006 552 170 177 10.1016/j.ejphar.2006.09. 011 17046746
15. Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. Pan SY, Dong H, Zhao XY, Xiang CJ, Fang HY, Fong WF, Ko KM, J Pharm Pharmacol 2008 60 399 340 18284822
16. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. Pan SY, Dong H, Yu ZL, Zhao XY, Xiang CJ, Wang H, Fong WF, Ko KM, J Pharm Pharmacol 2007 59 1657 1662 18053327
17. Ethanol extract of Fructus Schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity. Pan SY, Yu ZL, Dong H, Xiang CJ, Fong WF, Ko KM, Evid Based Complement Alternat Med 2011 10.1093/ecam/nep070729412. 2011.729412
18. Familial hypercholesterolemia: present and future management. Sjouke B, Kusters DM, Kastelein JJ, Hovingh GK, Curr Cardiol Rep 2011 13 527 536 10.1007/s11886-011-0219-9 21938413
19. The role of triglycerides in atherosclerosis. Talayero BG, Sacks FM, Curr Cardiol Rep 2011 13 544 552 10.1007/s11886-011-0220-3 21968696
20. Clinical review: Lipodystrophies: genetic and acquired body fat disorders. Garg A, J Clin Endocrinol Metab 2011 96 3313 3325 10.1210/jc.2011-1159 21865368
21. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Rubenfire M, Brook RD, Rosenson RS, Am J Med 2010 123 892 898 10.1016/j.amjmed.2010.03.024 20920687
22. Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. Guay V, Lamarche B, Charest A, Tremblay AJ, Couture P, Metabolism 2012 61 76 83 10.1016/j.metabol.2011.06.002 21816443
23. Millet consumption decreased serum concentration of triglyceride and C-reactive protein but not oxidative status in hyperlipidemic rats. Lee SH, Chung IM, Cha YS, Park Y, Nutr Res 2010 30 290 296 10.1016/j.nutres.2010.04.007 20534332
24. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. Xu RY, Wan YP, Fang QY, Lu W, Cai W, J Clin Biochem Nutr 2012 50 72 77 22247604
25. Histopathology of nonalcoholic fatty liver disease. Brunt EM, Tiniakos DG, World J Gastroenterol 2010 16 5286 5296 10.3748/wjg.v16.i42.5286 21072891
26. Relationship between familial combined hyperlipidemia and insulin resistance. Jackuliaková D, Vaverková H, Karásek D, Vnitr Lek 2008 54 1045 1053 19069677
27. Fenofibrate: a review of its use in dyslipidaemia. McKeage K, Keating GM, Drugs 2011 71 1917 1946 10.2165/11208090-000000000-00000 21942979
28. Fenofibrate and metabolic syndrome. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK, Endocr Metab Immune Disord Drug Targets 2010 10 138 148 20406163
29. Laboratory investigation of dysfunctional HDL. Guo ZG, Li C, Zhong JK, Tu Y, Xie D, Chem Phys Lipids 2012 165 32 37 10.1016/j.chemphyslip.2011.10.005 22064068
30. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. Kondo K, Sugioka T, Tsukada K, Aizawa M, Takizawa M, Shimizu K, Morimoto M, Suematsu M, Goda N, Adv Exp Med Biol 2010 662 77 82 10.1007/978-1-4419-1241-1-10 20204774
31. Possible involvement of oxidative stress in fenofibrate-induced hepatocarcinogenesis in rats. Nishimura J, Dewa Y, Okamura T, Muguruma M, Jin M, Saegusa Y, Umemura T, Mitsumori K, Arch Toxicol 2008 82 641 654 10.1007/s00204-007-0278-2 18253720
32. Evaluation of in vivo genotoxic potential of fenofibrate in rats subjected to two-week repeated oral administration. Tawfeeq MM, Suzuki T, Shimamoto K, Hayashi H, Shibutani M, Mitsumori K, Arch Toxicol 2011 85 1003 1011 10.1007/s00204-010-0628-3 21127841
33. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms. Yamasaki D, Kawabe N, Nakamura H, Tachibana K, Ishimoto K, Tanaka T, Aburatani H, Sakai J, Hamakubo T, Kodama T, Doi T, Eur J Cell Biol 2011 90 657 664 10.1016/j.ejcb.2011.02.005 21514001
34. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, Guo L, Toxicol Pathol 2009 37 521 535 10.1177/0192623309336152 19458390
35. Protective effects of green tea polyphenols on human HepG2 cells against oxidative damage of fenofibrate. Jiao HL, Ye P, Zhao BL, Free Radic Biol Med 2003 35 1121 1128 10.1016/S0891-5849(03)00506-9 14572614
36. Acute cholestatic hepatitis induced by fenofibrate. Hajdu D, Aiglová K, Vinklerová I, Urbánek K, J Clin Pharm Ther 2009 34 599 602 10.1111/j.1365-2710.2009.01029.x 19744016
37. Emerging therapeutic strategies to enhance HDL function. Redondo S, Martínez-González J, Urraca C, Tejerina T, Lipids Health Dis 2011 10.1186/1476-511X-10-175
38. Increased LDL susceptibility to oxidation accelerates future carotid artery atherosclerosis. Aoki T, Abe T, Yamada E, Matsuto T, Okada M, Lipids Health Dis 2012 10.1186/1476-511X-11-4
39. Advancing therapy for hypercholesterolemia. Toutouzas K, Drakopoulou M, Skoumas I, Stefanadis C, Expert Opin Pharmacother 2010 11 1659 1672 10.1517/14656561003774080 20509773
40. Synergistic hepatoprotective effect of Schisandrae lignans with Astragalus polysaccharides on chronic liver injury in rats. Yan F, Zhang QY, Jiao L, Han T, Zhang H, Qin LP, Khalid R, Phytomedicine 2009 16 805 813 10.1016/j.phymed.2009.02.004 19345075
41. Effect of a lignan-enriched fructus schisandrae extract on hepatic glutathione status in rats: protection against carbon tetrachloride toxicity. Ko KM, Ip SP, Poon MK, Wu SS, Che CT, Ng KH, Kong YC, Planta Med 1995 61 134 137 10.1055/s-2006-958032 7753920
42. Preparative separation and purification of deoxyschisandrin and gamma-schisandrin from Schisandra chinensis (Turcz.) Baill by high-speed counter-current chromatography. Huang T, Shen P, Shen Y, J Chromatogr A 2005 1066 239 242 10.1016/j.chroma.2005.01.025 15794577
43. Studies on extraction process of Fructus Schisandrae chinensis and Fructus Ligustri lucidi in gandening tablet. Pan WJ, Xiao XH, Xiao X, Yuan HL, Zhao YL, China J Chin Mater Med 2004 29 743 745 Chinese
44. Studied on the chemical constituents of Schizandra chinesis. Dai HF, Zhou J, Peng ZG, Tan NH, Nat Prod Res Dev 2000 13 24 26 Chinese
45. Application of ultrahigh-performance liquid chromatography coupled with mass spectrometry for analysis of lignans and quality control of Fructus Schisandrae chinensis. Zhang WD, Wang Q, Wang Y, Wang XJ, Pu JX, Gu Y, Wang R, J Sep Sci 2012 10.1002/jssc.201200393
46. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. Valasek MA, Clarke SL, Repa JJ, J Lipid Res 2007 48 2725 2735 10.1194/jlr.M700345-JLR200 17726195
47. Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Večeřa R, Zachařová A, Orolin J, Strojil J, Skottová N, Anzenbacher P, Biopharm Drug Dispos 2011 32 482 487 10.1002/bdd.774 21968795
48. Role of the PPAR-α agonist fenofibrate in severe pediatric burn. Elijah IE, Børsheim E, Maybauer DM, Finnerty CC, Herndon DN, Maybauer MO, Burns 2012 38 481 486 10.1016/j.burns.2011.12.004 22226866
49. Effects of fenofibrate on lipid metabolism in adipose tissue of rats. Ferreira AV, Parreira GG, Green A, Botion LM, Metabolism 2006 55 731 735 10.1016/j.metabol.2006.01.020 16713430
50. Effects of Doxorubicin and Fenofibrate on the activities of NADH oxidase and citrate synthase in mice. Yao CX, Li WY, Zhang SF, Zhang SF, Zhang HF, Zang MX, Basic Clin Pharmacol Toxicol 2011 109 452 456 10.1111/j.1742-7843.2011. 00748.x 21711451
51. Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. Chu JH, Wang H, Ye Y, Chan PK, Pan SY, Fong WF, Yu ZL, World J Gastroenterol 2011 17 2379 2388 10.3748/wjg.v17.i19.2379 21633637
52. Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Yu HY, Wang BL, Zhao J, Yao XM, Gu Y, Li Y, Toxicology 2009 261 112 118 10.1016/j.tox.2009.04.058 19427351
53. Protective effect of bicyclol against acute fatty liver induced by tetracycline in mice. Tang T, Li Y, Acta Pharm Sin 2008 43 23 28 Chinese
54. High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia. Pan SY, Yang R, Han YF, Dong H, Feng XD, Li N, Geng W, Ko KM, Acta Pharmacol Sin 2006 27 673 678 10.1111/j.1745-7254.2006.00332.x 16723084